Beth Garner

Elizabeth (Beth) Garner, MD, MPH, is a seasoned pharmaceutical executive with a career-long focus on addressing unmet needs in women's health. Beth is currently CEO of Sena Therapeutics, a startup developing first-in-class medicines for PMOS. Most recently, she served as U.S. Chief Scientific Officer at Ferring Pharmaceuticals. Her prior C-suite roles include Chief Medical Officer at ObsEva and Agile Therapeutics, where she was instrumental in securing FDA approval of TWIRLA® (a low-dose contraceptive patch) and EMA approval of YSELTY® (linzagolix, for uterine fibroids and endometriosis). Earlier, she held leadership positions at Myriad Genetics, Abbott Laboratories, and Merck Research Laboratories, contributing to the development of Orilissa (for endometriosis) and the Gardasil/Gardasil 9 vaccines. Dr. Garner is the Board Chair of NUA Surgical, a startup innovating in surgical solutions for women. She is also Immediate Past President of the American Medical Women's Association (AMWA) and a Founder and Steering Committee member of Women's Health Advocates (WHA). Beth earned joint MD and MPH degrees from Harvard Medical School and Harvard School of Public Health, completed OB/GYN residency at Brigham and Women's/Massachusetts General Hospitals, and a gynecologic oncology fellowship at Brigham and Women's/Dana-Farber Cancer Institute.